Levi M, Roem D, Kamp A M, de Boer J P, Hack C E, ten Cate J W
Centre for Haemostasis, Thrombosis, Atherosclerosis and Inflammation Research, University of Amsterdam, The Netherlands.
Thromb Haemost. 1993 Feb 1;69(2):141-6.
It has been shown that the most important inhibitor of plasmin is alpha 2-antiplasmin, however, other protease inhibitors are able to inhibit this proteolytic enzyme as well. The contribution of the various protease inhibitors to the inhibition of plasmin in vivo has never been quantitatively assessed. To assess the relative contribution of the different protease inhibitors on the inhibition of plasmin we developed a series of sensitive immunoassays for the detection of complexes between plasmin and the protease inhibitors alpha 2-antiplasmin, alpha 2-macroglobulin, antithrombin III, alpha 1-antitrypsin and C1-inhibitor, utilizing monoclonal antibodies that are specifically directed against complexed protease inhibitors and a monoclonal antibody against plasmin. It was confirmed that alpha 2-antiplasmin is the most important inhibitor of plasmin in vivo, however, complexes of plasmin with alpha 2-macroglobulin, antithrombin III, alpha 1-antitrypsin- and C1-inhibitor were also detected. Particularly during activation of fibrinolysis complexes between plasmin and inhibitors other than alpha 2-antiplasmin were detected. It was observed that during different situations the inhibition profile of plasmin was not constant e.g. in patients with diffuse intravascular coagulation plasma levels of plasmin-alpha 1-antitrypsin and plasmin-C1-inhibitor were increased whereas in plasma from patients who were treated with thrombolytic agents complexes of plasmin with alpha 2-macroglobulin and with antithrombin III were significantly elevated. In conclusion, we confirmed the important role of alpha 2-antiplasmin in the inhibition of plasmin, however, in situations in which fibrinolysis is activated other protease inhibitors also account for the inhibition of plasmin in vivo.(ABSTRACT TRUNCATED AT 250 WORDS)
已表明纤溶酶最重要的抑制剂是α2-抗纤溶酶,然而,其他蛋白酶抑制剂也能够抑制这种蛋白水解酶。各种蛋白酶抑制剂在体内对纤溶酶抑制作用的贡献从未得到过定量评估。为了评估不同蛋白酶抑制剂对纤溶酶抑制作用的相对贡献,我们开发了一系列灵敏的免疫测定法,用于检测纤溶酶与蛋白酶抑制剂α2-抗纤溶酶、α2-巨球蛋白、抗凝血酶III、α1-抗胰蛋白酶和C1-抑制剂之间的复合物,利用特异性针对复合蛋白酶抑制剂的单克隆抗体和一种针对纤溶酶的单克隆抗体。已证实α2-抗纤溶酶是体内纤溶酶最重要的抑制剂,然而,也检测到了纤溶酶与α2-巨球蛋白、抗凝血酶III、α1-抗胰蛋白酶和C1-抑制剂的复合物。特别是在纤维蛋白溶解激活期间,检测到了纤溶酶与α2-抗纤溶酶以外的抑制剂之间的复合物。观察到在不同情况下,纤溶酶的抑制谱并非恒定不变,例如在弥散性血管内凝血患者中,纤溶酶-α1-抗胰蛋白酶和纤溶酶-C1-抑制剂的血浆水平升高,而在接受溶栓剂治疗的患者血浆中,纤溶酶与α2-巨球蛋白和抗凝血酶III的复合物显著升高。总之,我们证实了α2-抗纤溶酶在抑制纤溶酶方面的重要作用,然而,在纤维蛋白溶解被激活的情况下,其他蛋白酶抑制剂在体内也参与了对纤溶酶的抑制作用。(摘要截短至250字)